
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics is executing a methodical and strategic approach in employing their manufacturing and production expertise to develop and commercialize their leading cell therapy candidate COR1, while utilizing the experience gained from developing other candidates like OpRegen. Their proprietary AlloSCOPE platform, quality assurance assays, and TAI formulation set them apart as a leader in the biotech industry. Upcoming catalysts, such as the Phase 2a GAlette study and updates from collaborations with Roche and Genentech, are expected to further drive the company's growth and success. However, as with any biotech company, there are inherent risks in clinical development, regulatory approvals, partnerships, legal issues, and market competition.
Bears say
Lineage Cell Therapeutics is facing financial struggles as their Q4 2025 revenue was a low $6.6M compared to their operating expenses of $13.2M, resulting in a -$6.5M loss. Although they have multiple promising programs and collaborations in the pipeline, such as the OpRegen program and the William Demant Invest partnership, they may struggle to fund these initiatives with their current financial standing, leading to a potential slowdown in progress and growth. This, coupled with the lack of FDA approval for any of their programs at this time, may lead to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares